Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations.
about
The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's DiseasePsychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.Visual hallucinations in Parkinson's disease: a review and phenomenological survey.Neuropsychiatric complications of medical and surgical therapies for Parkinson's disease.Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease.Behavioral effects of levodopa.Pathophysiology and treatment of psychosis in Parkinson's disease: a review.Neuropsychiatric aspects of Parkinson's disease: recent advances.Neuropsychiatric co-morbidities in non-demented Parkinson's disease.An update expert opinion on management and research strategies in Parkinson's disease psychosisCerebral correlates of psychotic syndromes in neurodegenerative diseasesPsychotic symptoms in Parkinson's disease: pathophysiology and management.Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model.Treatment of behavioural symptoms and dementia in Parkinson's disease.Psychotic symptoms in Parkinson's disease. From description to etiology.Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options.New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins.Hallucinations, dreaming, and frequent dozing in Parkinson disease: impact of right-hemisphere neural networksHallucinations in Parkinson disease.The nonmotor symptoms of Parkinson's disease--an overview.Hallucinations in neurodegenerative diseases.Psychiatric issues in cognitive impairment.Visual hallucinations in Parkinson's disease: theoretical models.Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.The psychosis spectrum in Parkinson disease.Current Understanding of Psychosis in Parkinson's Disease.Orthostatic stability with intravenous levodopaDiagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group.Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations.Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition.I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging.Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease.Factors associated with drug-induced visual hallucinations in Parkinson's disease.The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease.Cerebral metabolic dysfunction in patients with dementia with Lewy bodies and visual hallucinations.Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations.Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline.Features associated with the development of hallucinations in Parkinson's disease.Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease.
P2860
Q26738456-18722022-0A1D-49D4-BB52-C28DF16F3754Q30249553-48FCBF41-7A0A-4852-9EAA-72C1E2E4DE4BQ34268928-6B6A9F72-51B1-4B07-A7A7-2456ED3C98ADQ34341299-7756DFB3-1EFD-491D-8075-E535090B52F6Q34438073-29C89340-CC54-42B4-BA8E-BB7D2F0B2541Q34452922-DB379158-5B88-4F59-8F89-5BBE3A04E871Q34610608-99F25F7F-C510-4C4C-A220-A795ECBBC617Q35103472-EDF331F0-0C3B-40F6-8338-43C2558BA141Q35149177-13B5CC46-260E-4CD3-8966-52A9731F19C9Q35154278-6E865E4F-FC11-47DF-97B6-509BD61EA391Q35194993-BC1F5A4E-F784-42EC-B1AF-6816110F38A0Q35779329-A5B11DC4-F7B7-4EDF-A3F6-81765CB66CA7Q35919426-9A3271FF-4CEF-47D3-BBC2-8475CECC41A0Q36089350-0E3FAB68-54A6-41BB-B782-93848C641F7CQ36184471-6BFEBAE0-550B-4A87-BA17-3B427958AFD3Q36492310-AA992211-E48B-483B-AE69-8CEF7C69C901Q37021326-461CF278-D9C0-4F37-AD1D-14425ABC41E9Q37071647-8BA945BD-3012-4A1A-BAAD-6F6CBBFA19F9Q37508601-5391BCE2-CA3A-4F6E-B3E6-78D692B860DCQ37699207-06215E37-B5B4-4717-A6B8-BD671029FE25Q37876971-04622012-1C15-43B4-85D7-76B266210245Q38206498-F72E2E13-34A6-4A1E-8D7F-981B086A858BQ38243013-4D8AF125-18E1-4159-A35F-5A91E2FCB159Q38258699-C7C61CBB-7CF6-4800-BB95-B5125F0F8AFBQ38662579-2F9C3D58-CBD4-4114-9DE9-0F61731B34A4Q38768169-DDEBF00A-AE98-4719-B6E8-38923D3DCE7EQ38954642-45941DC3-1F96-4A64-8E8E-B29EF7964EA2Q40577673-F46FFAEC-F1EB-48B7-A4BF-B8D3FC188719Q42610702-D9DEC166-6972-4D40-81A7-3AE51EE77499Q42970955-C29EBEFF-1E37-4362-9058-DB9081F6D7DEQ43375910-5607E99C-DA43-4E32-9FE6-EE01A5D5FE15Q43725039-FBDFFEAA-A1E6-4679-8476-662E00B0FA29Q44063087-AFEEF045-C335-436E-B7A2-5C27E52FAFCCQ44489283-178B1A51-36AE-4C25-A811-E8B556EA6A98Q44580067-3A1DD0D7-9E52-471C-8E44-F39EF7820C33Q46597682-2214983F-DEF8-4205-9F52-C0F068D61971Q46713971-C5EE4FA8-09AC-4593-A8F6-8E03AEC30EF9Q48090869-4CA6C235-A1DD-45F9-BE75-BADD65AFB162Q48433557-67412756-970F-4A8F-8AE8-27AC628F07A2Q48614497-2AA5863C-F33D-45E5-B3DA-FA6BA2C4B5D6
P2860
Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Intravenous levodopa in halluc ...... ot precipitate hallucinations.
@en
Intravenous levodopa in halluc ...... ot precipitate hallucinations.
@nl
type
label
Intravenous levodopa in halluc ...... ot precipitate hallucinations.
@en
Intravenous levodopa in halluc ...... ot precipitate hallucinations.
@nl
prefLabel
Intravenous levodopa in halluc ...... ot precipitate hallucinations.
@en
Intravenous levodopa in halluc ...... ot precipitate hallucinations.
@nl
P2093
P921
P356
P1433
P1476
Intravenous levodopa in halluc ...... ot precipitate hallucinations.
@en
P2093
P304
P356
10.1212/WNL.50.2.515
P407
P577
1998-02-01T00:00:00Z